

1 **A third dose of inactivated vaccine augments the potency, breadth,**
2 **and duration of anamnestic responses against SARS-CoV-2**

3
4
5 **Authors:** Kang Wang^{1§}, Yunlong Cao^{3§}, Yunjiao Zhou^{2§}, Jiajing Wu^{4,§}, Zijing Jia^{1§}, Yaling Hu^{5§},
6 Ayijiang Yisimayi³, Wangjun Fu¹, Lei Wang¹, Pan Liu¹, Kaiyue Fan¹, Ruihong Chen^{1,6}, Lin
7 Wang⁵, Jing Li⁵, Yao Wang³, Xiaoqin Ge⁵, Qianqian Zhang², Jianbo Wu², Nan Wang¹, Wei Wu²,
8 Yidan Gao², Jingyun Miao⁷, Yinan Jiang⁷, Lili Qin⁷, Ling Zhu¹, Weijin Huang⁵, Yanjun Zhang⁹,
9 Huan Zhang⁸, Baisheng Li⁸, Qiang Gao⁵, Xiaoliang Sunney Xie^{3*}, Youchun Wang^{4*}, Qiao
10 Wang^{2*} and Xiangxi Wang^{1,6*}

11
12 **Affiliation:**

13 ¹ CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute
14 of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

15 ² Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical
16 Sciences; Shanghai Institute of Infectious Disease and Biosecurity; Shanghai Medical College,
17 Fudan University, Shanghai 200032, China

18 ³ Beijing Advanced Innovation Center for Genomics (ICG), Biomedical Pioneering Innovation
19 Center (BIOPIC), School of life Science, Peking University, Beijing 100091, China

20 ⁴ Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product
21 Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China

22 ⁵ Sinovac Biotech Ltd, Beijing, China

23 ⁶ Guangzhou Laboratory, Guangzhou, Guangdong, China, 510320

24 ⁷ Acrobiosystems Inc, Beijing, China

25 ⁸ Guangdong Provincial Center for Disease Control and Prevention

26 ⁹ Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention,
27 Hangzhou, China

28
29 *Correspondence to: X.W. (Email: xiangxi@ibp.ac.cn) or Q.W. (Email: wangqiao@fudan.edu.cn)
30 or Y.W. (Email: wangyc@nifdc.org.cn) or X.S.X. (Email: sunneyxie@biopic.pku.edu.cn)

31 [§] These authors contributed equally to this work.

32

33 **Abstract: (~150 words)**

34 Emergence of variants of concern (VOC) with altered antigenic structures and waning
35 humoral immunity to SARS-CoV-2 are harbingers of a long pandemic. Administration
36 of a third dose of an inactivated virus vaccine can boost the immune response. Here,
37 we have dissected the immunogenic profiles of antibodies from 3-dose vaccinees, 2-
38 dose vaccinees and convalescents. Better neutralization breadth to VOCs, expeditious
39 recall and long-lasting humoral response bolster 3-dose vaccinees in warding off
40 COVID-19. Analysis of 171 complex structures of SARS-CoV-2 neutralizing
41 antibodies identified structure-activity correlates, revealing ultrapotent, VOCs-
42 resistant and broad-spectrum antigenic patches. Construction of immunogenic and
43 mutational heat maps revealed a direct relationship between “hot” immunogenic sites
44 and areas with high mutation frequencies. Ongoing antibody somatic mutation,
45 memory B cell clonal turnover and antibody composition changes in B cell repertoire
46 driven by prolonged and repeated antigen stimulation confer development of
47 monoclonal antibodies with enhanced neutralizing potency and breadth. Our findings
48 rationalize the use of 3-dose immunization regimens for inactivated vaccines.

49

50

51

52 **One sentence summary**

53 A third booster dose of inactivated vaccine produces a highly sifted humoral immune
54 response *via* a sustained evolution of antibodies capable of effectively neutralizing
55 SARS-CoV-2 variants of concern.

56

57

58

59

60 **Main Text:**

61 The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe
62 acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for one and a
63 half years, resulting in an unprecedented public health crisis with over 4 million
64 deaths globally. Progress in halting this pandemic seems slow due to the emergence
65 of variants of concern (VOC), such as the B.1.1.7 ([Alpha](#)), B.1.351 ([Beta](#)), P.1
66 ([Gamma](#), also known as B.1.1.28.1) and more recent B.1.617.2 ([Delta](#)), that appear
67 to be high transmissible and more resistant to neutralizing antibodies ([1-4](#)). While
68 several types of COVID-19 vaccines are being deployed at a large scale, new variants
69 are thought to be responsible for re-infections, either after natural infection or after
70 vaccination, as observed in Brazil and the United States, respectively ([5, 6](#)). Closely
71 correlated with these, a general decrease in immune protection against SARS-CoV-
72 2 variants within 6-12 months after the primary infection or vaccination is also
73 observed ([6-8](#)). The prospect of genetic recombination and antigenic drift in recent
74 SARS-CoV-2 variants together with non-uniform immune protections arising from
75 heterogeneously waning humoral immunity in COVID-19 convalescent or
76 vaccinated individuals, point to the potential risks of a long-term pandemic that could
77 endanger the global human health, diminishing social, economic and outdoor leisure
78 activities. A plausible approach to solving this problem is the administration of a
79 third dose of the vaccine somewhere between 6 and 12 months after the 2nd dose of
80 vaccination for enhancing and prolonging the protection. However, not much is
81 known about the immunogenic features of such a booster dose of a COVID-19 vaccine.
82 In addition, there are large gaps in our understanding about correlating immunogenic
83 findings from surrogate endpoints to gauge vaccine efficacy.

84

85 The CoronaVac, a 2-dose β -propiolactone-inactivated vaccine against COVID-19,
86 has been approved for emergency use by the World Health Organization ([9, 10](#)). In
87 human clinical trials (phase I/II, registration number: NCT04352608), a subgroup
88 with a 3-dose immunization schedule at months 0, 1, 7 was also included. To evaluate
89 immune features, we recruited 22 COVID-19 convalescents, 6 healthy participants
90 (SARS-CoV-2 negative, confirmed by RT-PCR) and 38 volunteers who received

91 either 2 or 3 doses of the Coronavac vaccine for blood donation. The volunteers
92 ranged from 16 to 69 years old (median 33); 30 (45.5%) were men and 36 (54.5%)
93 were women. None of the volunteers recruited for vaccination was infected by
94 SARS-CoV-2 prior to the study. Blood samples from convalescents and vaccinees
95 collected 1.3 months after infection and the indicated times after vaccination were
96 used in this study, respectively, to compare humoral immune responses elicited
97 against circulating SARS-CoV-2 variants.

98
99 Neutralizing antibodies (NAbs) are a major correlate of protection for many viruses,
100 including SARS-CoV-2, and have also provided the best correlate of vaccine
101 efficacy. Several types of SARS-CoV-2 neutralization assays have been described
102 using either live SARS-CoV-2 or a pseudo-typed reporter virus carrying SARS-CoV-
103 2 spike protein (S). Both types of assays could yield reproducible neutralizing titers,
104 with the pseudo-typed virus neutralization assay exhibiting higher sensitivity ([11](#),
105 [12](#)). Neutralizing activity of plasma samples from 66 participants was measured
106 against WT, B.1.351, P.1 and B.1.617.2 using live SARS-CoV-2 and VSV-
107 pseudoviruses with the S from WT, B.1.1.7, P.1 variants and SARS-CoV ([Fig. 1](#)).
108 The geometric mean half-maximal neutralizing titers (GMT NT₅₀) against live
109 SARS-CoV-2 in plasma obtained from convalescents and from vaccinees (4 weeks
110 after the final vaccination) suggest an approximately 60% higher neutralizing
111 activity against WT after 3-dose inoculation when compared with 2-dose
112 administration, and 20% higher than those from convalescents ([Fig. 1A](#)).
113 Interestingly, for the samples from the convalescents, 2-dose and 3-dose vaccinees,
114 neutralizing titers against B.1.351 were, on average, 7.7-fold, 5.7-fold and 3.0-fold
115 reduced, respectively, compared with WT ([Fig. 1A](#)). Similarly, fold decreases in
116 neutralization ID₅₀ titers against P.1 and B.1.617.2 for the three cohorts were 5.3, 4.3
117 and 3.1, and 5.3, 3.7 and 2.3, respectively ([Fig. 1A](#)). Overall, plasma of the 3-dose
118 vaccinees displayed minimal reduction in neutralization titers against several
119 authentic VOCs compared to the convalescents and 2-dose vaccinees ([Fig. 1A](#)).
120 Remarkably, ~41% (9/22) and 50% (6/12) samples from the convalescents and 2-
121 dose vaccinees, respectively, failed to reach 50% neutralization at a plasma dilution

122 of 1: 10, with ~14% (3/22) and 16% (2/12) showing a near ineffectiveness in
123 neutralizing B.1.351 *in vitro* (Fig. 1A). By contrast, only 1 out of 14 samples from
124 the 3-dose vaccinees exhibited a weak neutralizing titer below 10 (Fig. 1A).
125 Importantly, the 3-dose vaccinees showed over 2.5-fold higher neutralizing potency
126 against B.1.617.2 than the convalescents and 2-dose vaccinees (Fig. 1A). The GMT
127 NT₅₀ values measured by a VSV-pseudovirus with the WT S were 840, 660 and 1,176
128 for convalescents, 2-dose and 3-dose vaccinees, respectively, which were 8-10-fold
129 greater than those determined by live WT SARS-CoV-2 (Fig. 1A, 1B), confirming
130 higher sensitivity of pseudovirus-based assays in determining neutralizing titers. In
131 line with the results of live SARS-CoV-2 neutralization assay, the mean fold decrease
132 in the neutralization of B.1.1.7 relative to the WT was 2.8-fold for convalescents,
133 2.2-fold for 2-dose vaccinees and 1.7-fold for 3-dose vaccinees (Fig. 1B). Similarly,
134 plasma from convalescents, 2-dose and 3-dose vaccinees exhibited a 4.5-fold, 2.9-
135 fold and 2.4-fold reduction, in NAb titers against P.1, respectively, when compared
136 to the WT (Fig. 1B). These results reveal that a third-dose boost of inactivated
137 vaccine leads to enhanced neutralizing breadth to SARS-CoV-2 variants, bolstering
138 the potential to ward off VOCs effectively when compared to convalescent plasma.
139 Of note, neither vaccination nor SARS-CoV-2 infection boosts distinct neutralizing
140 potency against SARS-CoV, presumably due to the relatively far phylogenic
141 relationship (Fig. 1B).

142

143 To seek information on potential binding-neutralization correlates, the abilities of
144 antibodies present in plasma to bind the receptor-binding domain (RBD), N-terminal
145 domain (NTD), S-trimer and nucleoprotein (N) from SARS-CoV-2 and its variants
146 were measured by enzyme-linked immunosorbent assay (ELISA). As expected, all
147 COVID-19 convalescents and vaccinees exhibited high anti-RBD, anti-NTD, anti-S
148 and anti-N titers for SARS-CoV-2 variants, but weak antibody reactivity to SARS-
149 CoV (Fig. 1C and fig. S1). Unexpectedly, the amount of N-specific IgG elicited by
150 2-dose and 3-dose vaccination schedules was 2-6-fold lower than those of
151 convalescents, and 2-6-fold lower than the antibodies targeting S or RBD in
152 vaccinees, reflecting distinct serological profiles (Fig. 1C and fig. S1). Overall

153 plasma neutralizing activity against the WT was substantially correlated with anti-S
154 and anti-RBD binding titers in ELISA. However, only marginal correlates between
155 binding and neutralization potency were established for VOCs (fig. S2). In spite of
156 this, a 3-dose administration elicits a broader range of antibody binding activities to
157 VOCs with minimal decreasing folds than those of 2-dose vaccination and
158 convalescents (Fig. 1D and fig. S2).

159

160 To evaluate the nature of humoral immune response elicited by a booster dose of
161 CoronaVac, the S-specific IgA, IgM and IgG titers and neutralizing activities against
162 SARS-CoV-2 variants were monitored before and 4 weeks after the third
163 immunization. S-specific IgM and IgA titers were generally lower and were not
164 significantly boosted in response to the third-dose vaccination (Fig. 1E). Similar to
165 most convalescents (2), approximately 80~90% of both anti-S IgG and NAb titers
166 against the WT waned 6 months after the second vaccination (13), while the third-
167 dose administration of CoronaVac boosted these titers by ~20-fold at 4 weeks post
168 vaccination (Fig. 1E and F). Significantly, vaccinees 6 months after the second
169 immunization did not have detectable *in vitro* neutralizing activities against B.1.351,
170 P.1 and B.1.617.2, while all vaccinees exhibited a robust recall humoral response to
171 efficiently neutralize circulating variants post the third-dose vaccination (Fig. 1E and
172 F). To further characterize the expeditiousness, longevity and immunological
173 kinetics of recall response stimulated by the third-dose immunization, neutralizing
174 potencies at days 0, 7, 14, 28, 90 and 180 post the third-dose vaccination were
175 determined (Fig. 1G and H). Remarkably, NAb titer surged by ~8-fold (from 7 to 53)
176 at week 1, peaked by ~25-fold increase (up to 177) at week 2 after the 3rd-booster
177 and slowly decreased over time (Fig. 1G). Notably, NAb titer was maintained at
178 around 60 on 180 days post the 3rd-booster, comparable to the high level of NAb titer
179 elicited by the 2-dose administration (Fig. 1H). Taken together, these serological
180 results reveal a third-dose booster can elicit an expeditious, robust and long-lasting
181 recall humoral response.

182

183 The molecular mechanism underlying these potent, broad and durative antibody

184 responses elicited by a third-dose booster 6 months after the administration of the
185 second dose of the vaccine, might involve ongoing antibody somatic mutation and
186 evolution of antibody by affinity maturation through prolonged and repeated antigen
187 stimulation (14, 15). Although circulating antibodies derived from plasma cells wane
188 over time, long-lived immune memory can persist in expanded clones of memory B
189 cells (16). Thereby, we used flow cytometry to sort the SARS-CoV-2 S-trimer-
190 specific memory B cells from the blood of seven selected CoronaVac vaccinees,
191 including four samples from 3-dose vaccinees and three samples from 2-dose
192 vaccinees (Fig. 2A and fig. S3). The averaged percentage of S-binding memory B
193 cells in 3-dose vaccinees was substantially greater than those in 2-dose vaccinees
194 (Fig. 2A and fig. S3). Due to differences in labeling strategies employed for sorting
195 SARS-CoV-2-specific B cells, the above percentage of memory B cells was not
196 directly comparable with those reported in naturally infected individuals and in
197 mRNA vaccinated individuals. The gated double-positive cells were single cell
198 sorted and immunoglobulin heavy (*IGH*; IgG isotype) and light (*IGL* or *IGK*) chain
199 genes were amplified by nested PCR. Overall, we obtained 422 and 132 paired heavy
200 and light chain variable regions from S-binding IgG⁺ memory B cells from four 3-
201 dose and three 2-dose vaccinees, respectively (Fig. 2B and fig. S4). Surprisingly,
202 expanded clones of cells comprised 45-61% of the overall S-binding memory B
203 compartment in 3-dose vaccinees, which is approximately 2-fold higher than those
204 in COVID-19 convalescents and in mRNA or 2-dose vaccinated individuals (Fig. 2B
205 and C). When compared to 2-dose vaccinees, the increase in the number of persistent
206 clones and various clonal compositions in 3-dose vaccinated group suggested an
207 ongoing clonal evolution (Fig. 2B and C). Shared antibodies with the same
208 combination of *IGHV* and *IGLV* genes in 3-dose vaccinees comprised ~20% of all
209 the clonal sequences. Similar to natural infection and mRNA vaccination (2, 14, 16),
210 *IGHV3-30*, *IGHV3-53* and *IGHV1-69* remained significantly over-represented in 3-
211 dose vaccinees (fig. S5). Meanwhile, notable differences in the frequency of human
212 V genes between 3-dose vaccinated and the other two groups were observed as well
213 (fig. S5). In 3-dose vaccinees, *IGHV3-21*, *IGHV4-39* and *IGHV7-4-1* were largely
214 abundant, but *IGHV5-51*, *IGHV3-66* and *IGHV1-2* were significantly scarce when

215 compared to the other two groups (fig. S5), indicative of memory B cell clonal
216 turnover. Notably, large-scale, single-cell sequencing datasets generated from two
217 cohorts of 2-dose, 3-dose vaccinees and a group of convalescents revealed no distinct
218 preference in the frequency of *V* genes at total B cell repertoire level (fig. S6),
219 suggesting that a large abundance of antibodies with low expression or affinities exist
220 in B cells. Additionally, the number of nucleotide mutations in the *V* gene in 3-dose
221 vaccinees is higher than those in both 2-dose vaccinees and naturally infected
222 individuals assayed after 1.3 and 6.2 months, but slightly lower than those in
223 convalescent individuals 1 year after infection (Fig. 2D), revealing ongoing somatic
224 hypermutation of antibody genes. There was no significant difference in the length
225 of the IgG CDR3 between vaccinated (either mRNA or inactivated) and convalescent
226 (after 1.3 or 6.2 or months) groups (fig. S7). These results reveal that a third-dose
227 booster 6 months after the second vaccination elicits an enhanced and anamnestic
228 immune response, which is led by clonal evolution of memory B cell and ongoing
229 antibody somatic mutations, resulting in enhanced neutralizing potency, breadth and
230 longevity of the immune response against SARS-CoV-2.

231

232 To further explore the immunogenic characteristics of the antibodies obtained from
233 memory B cells in 3-dose vaccinees, 48 clonal antibodies, designated as XGv01 to
234 XGv50 (no expression for XGv37 and XGv48) were expressed and their antigen
235 binding abilities verified by ELISA (fig. S8). Biolayer interferometry affinities (BLI)
236 measurements demonstrated that all antibodies bound to WT SARS-CoV-2 at sub-
237 nM levels (fig. S9 and table S1). The normalized geometric mean ELISA half-
238 maximal concentration (EC_{50}) revealed that all antibodies ($EC_{50}=4.5$ ng/ml) obtained
239 from 3-dose vaccinees, in particular RBD-specific mAbs ($EC_{50}=3.5$ ng/ml),
240 possessed higher binding activities than RBD-mAbs from early convalescents (at 1.3
241 and 6.2 months after infection, $EC_{50}=5.0$ and 6.8 ng/ml, respectively) and mRNA
242 ($EC_{50}=4.4$ ng/ml) vaccinated individuals (2, 14-18), but were comparable to those
243 from late convalescent individuals ($EC_{50}=2.6$ ng/ml) assessed at 12 months after
244 infection (Fig. 2E). These results indicate the possibility of the loss of antibodies
245 with low binding affinities over time or an ongoing increase in affinity under the

246 repeated exposures of antigen. Among these antibodies tested, 26 bound to RBD, 16
247 targeted NTD, and 6 interacted with neither RBD nor NTD, but bound S1 (S1/non-
248 RBD-NTD) (fig. S9 and table S1). Pseudovirus neutralization assay revealed that all
249 RBD-specific antibodies, 10 (~60%) of the 16 NTD-directed antibodies and 3
250 (~50%) of the 6 S1/non-RBD-NTD antibodies were neutralizing, presenting a
251 relatively high ratio for NAbs (Fig. 2F, fig. S10 and table S2). Authentic SARS-CoV-
252 2 neutralization assay results largely verified their neutralizing activities, albeit with
253 that higher concentrations were required for some NAbs (fig. S11). Compared to
254 RBD antibodies, many NTD NAbs exhibited very limited neutralizing activities.
255 Notably, approximately 30% of RBD antibodies showed extra potent activities with
256 half-maximal inhibitory concentration values (IC_{50}) < 0.1 nM. In line with binding
257 affinity, the normalized geometric mean IC_{50} of the RBD antibodies of 3-dose
258 vaccinees was 80 ng/ml, substantially lower than those from naturally infected
259 individuals (ranging from 1.3 to 6.2 months, IC_{50} =130-160 ng/ml) and mRNA
260 vaccinated individuals (IC_{50} =150 ng/ml), but similar to those from late convalescents
261 (IC_{50} =78 ng/ml) (Fig. 2E) (2, 14-18). The overall increased neutralizing potency
262 might have resulted from the ongoing accumulation of clones expressing antibodies
263 with tight binding and potent neutralizing activities. Our experimental observations
264 are consistent with a more recent study where antibodies generated from clonal B
265 cells after 12 months showed enhanced neutralizing activities (14, 15).

266

267 To examine the cross-reactivity against VOCs and other human coronaviruses,
268 binding responses of these antibodies to WT, B.1.1.7, P.1, B.1.351, B.1.617.2, SARS-
269 CoV, HuCoV NL63, HuCoV 229E and HuCoV HKU1 were measured. All but 2 of
270 the 48 antibodies showed strong cross-binding to SARS-CoV-2 VOCs and about one-
271 third of antibodies exhibited clear cross-reactivity to SARS-CoV, but none of these
272 bound to HuCoV NL63, HuCoV 229E or HuCoV HKU1 (fig. S12). For ~ 20% and
273 25% of RBD- and NTD-targeting antibodies, respectively, binding affinities against
274 B.1.351/B.1.617.2 were over 10-fold reduced compared with WT (Fig. 2E). To
275 further determine the neutralization breadth, the neutralizing activity of these
276 antibodies was assayed against five VOCs and SARS-CoV. Out of 26 RBD NAbs,

277 24 possessed cross-neutralization activity against all five SARS-CoV-2 VOCs (Fig.
278 2F and fig. S13). Among these, six RBD antibodies could cross-neutralize SARS-
279 CoV, of which 2 exhibited more potent neutralization activity against SARS-CoV
280 with IC₅₀ values of 41 and 73 ng/ml. However, most of the NTD and S1/non-RBD-
281 NTD NAbs lost their abilities to inhibit viral infection (Fig. 2F and fig. S13),
282 indicative of higher variations for the NTD in VOCs. In comparison with NAbs from
283 early convalescents, antibodies isolated from 3-dose vaccinees showed overall
284 enhanced neutralizing potency and breadth to VOCs.

285

286 RBD is one of the main targets of neutralization in SARS-CoV-2 and other
287 coronaviruses. Due to its inherent conformational flexibility, RBD exists in either an
288 “open” (ACE2 receptor accessible) or “closed” (ACE2 receptor inaccessible)
289 configuration (19, 20), bearing antigenic sites with distinct “neutralizing sensitivity”.
290 To dissect the nature of the epitopes of RBD targeted by NAbs, 171 SARS-CoV-2
291 RBD-targeting NAbs with available structures (2, 15, 21-82), including 8 cryo-EM
292 structures determined in this manuscript (fig. S14-S15 and table S3), were examined.
293 By using cluster analysis on epitope structures, the antibodies were primarily
294 classified into six sites (I, II, III, IV, V and VI) (Fig. 3A and fig. S16), that are related
295 to the four or five classes assigned in recent studies (22, 31). Additionally, we
296 superimposed structures of RBDs from these complex structures and calculated the
297 clash areas between any 2 NAbs (Fig. 3B). Both strategies yielded identical results.
298 Combining the results of the characterization of binding and neutralization studies
299 reported previously with those determined here, the key structure-activity correlates
300 for the six classes of antibodies were analyzed (Fig. 3). Antibodies with sites I, II and
301 III, most frequently elicited by SARS-CoV-2 early infection, target the receptor-
302 binding motif (RBM), and potently neutralize the virus by blocking the interactions
303 between SARS-CoV-2 and ACE2 (Fig. 3C and D). Class I antibodies, mostly derived
304 from *IGHV3-53/IGHV3-66* with short HCDR3s (generally <15 residues), recognize
305 only the “open” RBD, and make contact with K417 and N501, but not
306 L452/T478/E484 (Fig. 3C and D, and fig. S16-S17). Notably, mutations such as
307 K417N, L452R, T478K, E484K and N501Y, or combinations of these mutations,

308 identified in several VOCs like B.1.1.7, B.1.617.2, P.1 and B.1.351, have been
309 demonstrated to be key determinants for the viral escape of neutralization by many
310 NAbs (fig. S18) (1, 81). Approximately ~75% and 60% of class I NAbs were
311 significantly impaired in binding and neutralizing activities against B.1.351 as well
312 as P.1, respectively, due to the combined mutations of K417N/T and N501Y (Fig. 3D
313 and E, and fig. S18). Contrarily, Class III antibodies that are encoded by *IGHV1-2*
314 and other variable heavy (VH)-genes and bound to RBD either in “open” or “closed”
315 conformation, extensively associate with E484, and partially with L452, but not
316 K417/T478/N501 (Fig. 3D and fig. S17C). Interestingly, *IGHV3-53/IGHV3-66* RBD
317 antibodies with long HCDR3s (>15 residues) switch their epitopes from the site I to
318 site III, indicating a clear antigenic drift during the process of somatic
319 hypermutations (fig. S17C). Disastrously, over 90% class III antibodies showed a
320 complete loss of activity against B.1.351 as well as P.1 largely owing to an E484K
321 mutation (Fig. 3E). Against B.1.617.2, the substantially decreased activity of ~half
322 of the class III antibodies is presumably mediated by L452R (Fig. 3E). Class II
323 antibodies use more diverse VH-genes and target the patch lying between sites I and
324 III (Fig. 3D and fig. S19). Surprisingly, antibodies binding to site II possess relatively
325 lower specificity in recognition of epitope clusters ranging from K417, L452, S477,
326 E484 to N501 (fig. S16). Like site I, site II can only be accessed when the RBD is in
327 “open” conformation (Fig. 3A). As expected, the effects of mutations on the activity
328 of class II antibodies were severe, two-thirds of these antibodies had >10-fold fall in
329 neutralization activities against VOCs (Fig. 3E). Overall, the above analysis reveals
330 that the RBD mutations identified in several VOCs can significantly reduce and, in
331 some cases, even abolish the binding and neutralization of classes I to III antibodies,
332 albeit being the most potent neutralizing antibodies against WT SARS-CoV-2.

333

334 By contrast, antibodies of the other three classes recognize evolutionarily conserved
335 regions distinct from the RBM and some of these are often cross-reactive with other
336 sarbecoviruses (65-67, 79). The binding of class IV antibodies, albeit attached to the
337 apical shoulder of the RBM, is focused on a condensed patch that comprises residues
338 345-346, 440-441, 444-446, 448-450, which are not related to mutations observed in

339 VOCs (Fig. 3C and fig. S16). Related to the binding position, site IV epitopes,
340 accessible in both “open” and “closed” conformations, exist either as partially
341 overlapped with or outside ACE2 binding sites (Fig. 3A). Interestingly, class IV
342 antibodies can execute their neutralizations via multiple mechanisms, such as (i)
343 direct blockage of RBD-ACE2 associations, (ii) bridging adjacent “closed” RBDs to
344 lock the S-trimer into a completely closed prefusion conformation, (iii) blockage of
345 viral membrane fusion by locking conformational changes of the S-trimer, or (iv) Fc-
346 dependent effector mechanisms (31, 62, 67). Class IV antibodies, e.g. 1-57, 2-7, S309
347 and BD-812, hold the greatest potential for harboring ultra-potent neutralization
348 activity and markedly high tolerance to most VOCs (63, 67). Not surprisingly, all class
349 IV antibodies, but CV07-270, exhibited excellent neutralizing breadth and potency to
350 VOCs (Fig. 3E). The probable reason underlying the exception could be that CV07-
351 270 bears an unusually long HCDR3, directly contacting E484, distal to the site IV (46).
352 Site V locates beneath the RBM ridge, opposite to the site I, and adjacent to the site
353 III. None of the class V antibodies compete with ACE2 binding (Fig. 3D and fig.
354 S17). Due to ~40% targeting frequency to L452, B.1.617.2, but not other VOCs,
355 partially decreased the activities of some class V antibodies (Fig. 3E). Class VI
356 antibodies recognize a patch on one side of the RBD, distal from the RBM. Among
357 these, some compete with ACE2 binding, while some do not, and this largely depends
358 on the orientation/pose of the antibodies bound. Both sites V and VI contain cryptic
359 epitopes that are only accessible when at least one RBD is in the open state (Fig. 3A
360 and C). In some cases, e.g. FC08 and CR3022, belonging to class V and VI,
361 respectively, epitopes are only accessible in the prefusion S-trimer under the
362 condition that all RBDs are open, suggesting that binding of these antibodies would
363 facilitate the destruction of the prefusion S-trimer (83, 84). In spite of less potency,
364 antibodies targeting sites V to VI are mostly tolerant to the VOCs.

365

366 Low levels of NAbs elicited by either natural infection or vaccination during *in vivo*
367 viral propagation may impose strong selection pressure for viral escape, leading to
368 an increase in the number of SARS-CoV-2 variants. To further understand the drivers
369 of viral evolution, we constructed immunogenic and mutational heatmaps for RBD

370 using the 171 NAb complex structures to estimate *in vivo* NAb-targeting frequencies
371 on the RBD and viral mutation frequencies (calculated from the datasets in the
372 GISAID), respectively (Fig. 3D and fig. S19). Briefly, for each antibody, we
373 identified epitope residues and calculated the frequency of each RBD residue being
374 recognized by antibody. Immunogenic heatmap revealed that the epitope residues of
375 sites I to III showed predominantly higher NAb recognition frequencies (about 53.8,
376 55.0 and 49.2 antibodies per residue on average for site I, II and III, respectively)
377 compared with those of sites IV to VI (about 19.4, 9.1 and 14.3 antibodies per
378 residues on average for site IV, V and VI, respectively), suggesting that class I to III
379 antibody epitopes are “hot” immunogenic sites (Fig. 3D and fig. S19). In line with
380 this, residues within sites I to III exhibited dramatically higher mutation frequencies,
381 as revealed in circulating variants that include mutations of K417, L452, S477, T478,
382 E484 and N501 residues (Fig. 3D and fig. S19). Surprisingly, none of the top 9 hottest
383 immunogenic residues had a high mutation frequency. In particular, residues, such
384 as F486, Y489, Q493, L455, F456, *et.al* (top 5, having 96, 96, 81, 73 and 70
385 antibodies per residue, respectively) with large side chains exhibited extremely low
386 mutation frequencies in circulating SARS-CoV-2 strains (Fig. 3D and fig. S20). It’s
387 worthy to note that all these residues are extensively involved in the recognition of
388 ACE2. The buried surface area (BSA) of these residues upon binding to ACE2
389 confirmed that extensive interactions would be significantly reduced by amino acid
390 substitutions, thereby affecting ACE2-mediated viral entry. Thus, genetic, structural
391 and immunogenic analysis explains why mutations at these positions would not be
392 selected.

393

394 A few studies have reported that a subset of NTD-targeting antibodies can be as
395 potent as best-in-class RBD specific antibodies. They work *via* inhibiting a step post-
396 attachment to cells like blocking fusion of the virus to the host cell membrane (85-
397 88). We performed cluster analysis on 26 structures of the NTD-NAb complexes
398 (including 2 structures solved in this manuscript) (fig. S21A) (54, 85-93). A
399 dominant site α , defined as the “supersite” in more recent studies (85-88), comprising
400 of three flexible loops (N1, N3 and N5), is the largest glycan-free surface of NTD

401 facing away from the viral membrane (facing up). Antibodies targeting site α
402 generally exhibited the most potent neutralizing activity compared to other sites on
403 the NTD (85, 90) (fig. S21B and C). The NTD supersite antibodies are primarily
404 derived from a subset of VH-genes with an over-representation of *IGHV1-24*. Sites
405 β and γ , as the left and right flank clusters, construct a shallow groove beneath the
406 supersite and locate at the back of the groove, eliciting less potent antibodies. By
407 contrast, δ antibodies, bound to a patch beneath the groove have their Fab constant
408 domains directed downward toward the virus membrane (facing down) (fig. S21B
409 and C). In line with binding orientation, many of the δ antibodies were shown to
410 present infection enhancing activities *in vitro* (54, 90). Perhaps correlated with being
411 a “hot” immunogenic site that is amenable to potent neutralization, highly frequent
412 mutations, including a number of deletions within the NTD supersite were identified
413 in most VOCs under ongoing selective pressure, leading to significant reduction and
414 in some cases even complete loss of neutralization activity for these NTD supersite
415 NAbs (94).

416

417 More recent studies have reported that SARS-CoV-2 infection can produce a long-
418 lasting memory compartment that continues to evolve over 12 months after infection
419 with ongoing accumulation of somatic mutations, emergence of new clones and
420 increasing affinity of antibodies to antigens (14, 15). Consequently, an increase in
421 breadth and overall potency of antibodies produced by memory B cells over time has
422 been revealed (14), akin to the experimental observations elicited by a 3-dose
423 vaccination strategy using an inactivated vaccine described in this study. To
424 investigate whether changes in the frequency of distribution of the six types of RBD
425 antibodies is associated with evolution time, we collated and categorized human
426 SARS-CoV-2 NAbs from available literatures. For antibody clustering, we combined
427 structural and square competition matrix analysis for 273 RBD NAbs in total (Fig.
428 4A and fig. S22). In the earliest documented studies (before Dec 2020), NAbs
429 belonging to classes I to III were predominantly identified in early COVID-19
430 convalescent and 2-dose vaccinated individuals (defined as early time point),
431 accounting for up to ~80% of total antibodies. By contrast, a low ratio of NAbs from

432 IV to VI was reported possibly due to their less potent activities at the early time
433 point (Fig. 4A). In recent literatures (after Dec 2020), NAbs with enhanced
434 neutralizing potency and breadth from IV to VI have substantially been enriched in
435 the late convalescents or 3-dose vaccinees, almost equal in frequency to antibodies
436 from I to III and further becoming ascendant in individuals immunized with 3 doses
437 of inactivated vaccine (Fig. 4A). Differential frequency of distribution of antibody
438 types may provide an additional possible explanation for the observed enhanced
439 neutralizing breadth of plasma in late convalescent individuals and 3-dose vaccinees.
440 These results suggest that memory B cells display clonal turnover after about 6
441 months, subsequently resulting in changes in the composition of antibodies in B cell
442 repertoire and thereby partially contributing to enhanced activities of antibodies
443 secreted in the plasma over time. To explore the underlying mechanism, we measured
444 the binding affinities of 167 type-classified antibodies that are also further
445 categorized into early and late time point groups (table S1 and fig. S9). For the late
446 time group, there was a 10-20 fold increase in binding affinity for individual classes,
447 compared to those in the early time point group (Fig. 4B). In early time point group,
448 antibodies from IV to VI exhibited higher binding affinities to the RBD than those
449 from I to III, in particular, antibodies from V and VI despite limited numbers (Fig.
450 4B). Possibly higher affinities for these antibodies are required to accomplish
451 neutralization successfully. Thus, most antibodies from V and VI with low affinities
452 and activities might be screened out in the early time point. In the late point group,
453 sub- nM binding affinities for individual class antibodies with no distinct variations
454 were observed, reflecting ongoing affinity maturation over time. This might also
455 explain the observation that some antibodies, from I to III isolated in the late time
456 point possess potent cross-neutralization activities (Fig. 3E). Our antibody clustering
457 and V gene usage analysis suggests that individual class antibodies can be derived
458 from multiple V genes and the shared V gene antibodies belong to different classes.
459 To decipher the intrinsic trends in the relationship between binding affinity and
460 somatic hypermutation (SHM) rate, we determined the relative affinity (K_D) and
461 calculated the SHM rate of antibodies that are encoded by the same V gene and
462 belong to the same class. The measured K_D -SHM plots and K_D -SHM log-log plots of

463 class I antibodies (n=61), including 32 NAbs derived from *IGHV3-53*, show least
464 squares fitting of data to a power law with a strong correlation of -0.81 for *IGHV3-53*
465 antibodies (-0.55 for all class I antibodies) (Fig. 4C). The absolute value of its slope
466 corresponding to a free energy change per logarithm (base e) *SHM* of cal nmol^{-1} ,
467 where free energy change is $4.98RT + 1.48RT \ln(SHM)$ ($R = 2.0 \text{ cal K}^{-1} \text{ nmol}^{-1}$
468 and $T = 298 \text{ K}$). Antibodies with adequate numbers tested from II and III exhibited
469 similar trends by following a power law, among which *IGHV3-66* antibodies in class
470 II yielded a compelling correlation of -0.94 despite 6 plots involved in the fitting
471 (Fig. 4C). These trends indicate that as the SHM increase, the binding energy
472 increases and K_D value decreases.

473

474 More recently, the B.1.617.2 variant has contributed to another surge in COVID-19
475 cases worldwide, accounting for ~90% of new cases in the UK and >40% in the US,
476 despite the fact that increasing number of people have been vaccinated. Evaluation
477 of the effectiveness of several vaccines performed recently suggests that the efficacy
478 for VOCs correlates with full vaccination status and the time that has passed since
479 vaccination (95, 96). These may indicate that the effectiveness of the vaccines has
480 started to decline as months pass after vaccination due to fading immunity. Our
481 results demonstrate that a third-dose booster of inactivated vaccine can elicit an
482 expeditious, robust and long-lasting recall humoral response which continues to
483 evolve with ongoing accumulation of somatic mutations, emergence of new clones
484 and increasing affinities of antibodies to antigens, conferring enhanced neutralizing
485 potency and breadth. Collectively, our findings rationalize the use of 3-dose
486 vaccination regimens.

487

488

489 **Acknowledgments:** We thank Dr. Xiaojun Huang, Dr. Boling Zhu, Dr. Lihong Chen,
490 Dr. Xujing Li and Dr. Gang Ji for cryo-EM data collection, the Center for Biological
491 Imaging (CBI) in Institute of Biophysics for EM work and thank Dr. Yuanyuan Chen,
492 Zhenwei Yang for technical help with BLI experiments. We also thank Prof. David Ho
493 and Prof. Barton Ford Haynes for generous gift of the sequences of two reference
494 mAbs. Work was supported by the Strategic Priority Research Program

495 (XDB29010000, XDB37030000), CAS (YSBR-010), National Key Research and
496 Development Program (2020YFA0707500, 2018YFA0900801), Emergency Key
497 Program of Guangzhou Laboratory, Grant No. EKPG21-09 and Beijing Municipal
498 Science and Technology Project (Z201100005420017). Xiangxi Wang was supported
499 by Ten Thousand Talent Program and the NSFS Innovative Research Group (No.
500 81921005). **Author contributions:** X.W., Q.W., Y.W., X.S.X and Y.C. conceived,
501 designed and coordinated the experiments. Y.Z., A.Y., Y.W., Q.Z. and J-B.W. cloned
502 and produced antibodies. K.W., Z.J., K.F., J.M., Y.J. and L.Q. expressed and purified
503 all recombinant antigen proteins used in this manuscript. J-J.W., Y.H., L.W., J.L., X.G.,
504 Y-J.Z., H.Z. and B-S.L performed pseudovirus and authentic virus neutralization
505 experiments. K.W., L.W., P. L., WJ.F, N.W and L.Z performed structural study. Y.C.,
506 Y.Z., W.W. and Y.G. prepared PBMCs and flow cytometry sorting. Y.C. and A.Y.
507 performed 10X sequencing library construction. Z.J. and K.F performed BLI assay.
508 Y.H. and Q.G recruited volunteers and coordinated the collection of blood samples. All
509 authors analyzed data; X.W wrote the manuscript with input from all authors.
510 **Competing interests:** All authors have no competing interests. **Data and materials**
511 **availability:** Cryo-EM density maps of the SARS-CoV-2 S trimer in complex with
512 XGv013 or XGv043, the SARS-CoV-2 S trimer in complex with XGv004, XGv030
513 and XGv016; the SARS-CoV-2 S trimer in complex with XGv026 and XGv046, and
514 the SARS-CoV-2 S trimer in complex with XGv018, XGv038 and XGv42 have been
515 deposited at the Electron Microscopy Data Bank with accession codes EMD-UUUU,
516 EMD-WWWW, EMD-XXXX, EMD-YYYY and EMD-ZZZZ, respectively.

517

518

519

520


521

522

523

524

525 **Figure legends**



526

527 **Fig. 1 A 3rd-dose booster of an inactivated vaccine elicits an expeditious and**
 528 **long-lasting recall antibody response**

529 Plasma neutralizing activity evaluated by authentic SARS-CoV-2 (A) and pseudo-
 530 typed SARS-CoV-2 neutralization assays (B) Left: half-maximal neutralizing titer
 531 (NT₅₀) values for plasma from COVID-19 convalescents, 2-dose, 3-dose CoronaVac
 532 vaccine recipients (at week 4 after the last dose of vaccination) and negative controls
 533 (pre-COVID-19 historical control) against live SARS-CoV-2 WT, B.1.351, P.1 and
 534 B.1.617.2, and VSV-based SARS-CoV-2 pseudoviruses bearing WT or B.1.1.7 or P.1
 535 S protein. Black bars and indicated values represent geometric mean NT₅₀ values.
 536 Statistical significance was determined using the two-tailed Wilcoxon matched-pairs
 537 test. Experiments were repeated in triplicate. Dotted lines indicate the limit of
 538 detection. Right: fold decrease in neutralization for each variant relative to WT for

539 each cohort of plasma samples (calculated from the left datasets) is shown.

540 **(C)** IgG endpoint antibody responses specific to the N, RBD and S of WT SARS-
541 CoV-2 were measured in plasma samples collected from cohorts as described earlier.

542 **(D)** Fold decrease in specific binding to the RBD, NTD and S for each variant over
543 WT for each cohort of plasma samples as described above.

544 **(E)** IgA, IgM and IgG endpoint antibody titers specific to the S of WT SARS-CoV-
545 2 or its variants in plasma samples collected from vaccinees before and 4 weeks after
546 the 3rd-dose immunization.

547 **(F)** Neutralizing titers against live SARS-CoV-2 WT, P.1, B.1.351 and B.1.617.2 for
548 plasma from vaccinees before and 4 weeks after the 3rd-dose immunization. Black
549 bars and indicated values represent geometric mean NT₅₀ values.

550 **(G)** Longitudinal neutralizing titers of plasma from 3-dose vaccinees at days 0, 7,
551 14, 28, 90 and 180 post the 3rd-dose vaccination. The geometric mean NT₅₀ values
552 are labeled.

553 **(H)** Kinetics of the 3rd-dose booster elicited recall response as indicated during
554 monitoring of NAb titers at different time points. The green and blue curves show
555 the changes in kinetics of NAb titers for pre-3rd-dose and post-3rd-dose vaccination,
556 respectively.

557

558

559

560

561

562


563

564

565

566

567



568

569 **Fig. 2** Memory B cell antibodies elicited by a 3rd-dose booster of an inactivated
 570 vaccine

571 (A) Representative flow cytometry plots showing dual allophycocyanin (APC)-S-
 572 and phycoerythrin (PE)-S-binding B cells for vaccinees and control donor.

573 (B) Pie charts represent the distribution of antibody sequences from the four 3-dose
 574 vaccinees. The number in the inner circle is the number of sequences analyzed here.
 575 Pie-slice size is proportional to the number of clonally related sequences. The black
 576 outline indicates the frequency of clonally expanded sequences detected individually.
 577 Colored slices reveal clones that share the same *IGHV* and *IGLV* genes.

578 (C) Graph shows relative clonality among seven individuals who received 2-dose or
 579 3-dose of inactivated vaccines. Relative clonality for COVID-19 convalescents
 580 assayed at 1.3, 6.2 and 12 months after infection, as well as 2-dose mRNA vaccine
 581 recipients (2, 14, 18), previously described by Michel's group, was compared. Black

582 horizontal bars indicate mean values. Statistical significance was determined using
583 two-tailed t-test.

584 **(D)** Number of somatic nucleotide mutations in the *IGHV* (left) and *IGLV* (right) in
585 antibodies from vaccinees, including 2-dose or 3-dose of inactivated vaccines and 2-
586 dose of mRNA vaccines and COVID-19 convalescents assayed at 1.3, 6.2 and 12
587 months after infection (2, 14, 18).

588 **(E)** Normalized ELISA binding (EC_{50}) by antibodies isolated from the 3-dose
589 inactivated and 2-dose mRNA vaccinees (ref) as well as COVID-19 convalescents to
590 SARS-CoV-2 S trimer (left) and normalized pseudovirus neutralization activity
591 (IC_{50}) (right) against SARS-CoV-2 assayed at 1.3, 6.2 and 12 months after infection
592 (ref). Among these, eight antibodies reported by Michel's group were expressed and
593 assessed for both binding by ELISA and pseudovirus neutralization activity for
594 normalized comparison here. Black horizontal bars indicate mean values.

595 **(F)** BLI binding affinities (upper panel) and pseudo-typed virus neutralization
596 (bottom panel) by antibodies isolated from the 3-dose vaccinees to circulating SARS-
597 CoV-2 variants. Color gradient for upper panel indicates K_D values ranging from 0
598 (green), through 2.5 (yellow) and 5 (red) to 25 nM (purple). Gray suggests no/very
599 limited binding activity (>1000 nM). Color gradient for bottom panel indicates IC_{50}
600 values ranging from 0 (green), through 20 (yellow) and 200 (red) to 2000 ng/ml
601 (purple). Gray suggests no/very limited neutralizing activity (>2000 ng/ml).

602

603

604

605

606

607

608


609

619 six antibody classes.

620 **(C)** Surface representative model of six types of NAbs bound to the RBD. Fab
621 fragments of six representative antibodies are shown in different colors and the RBD
622 is colored in gray. Insets illustrate the antigenic patches targeted by six representative
623 antibodies. Dashed dots indicate the overlaps between two adjacent antigenic
624 patches.

625 **(D)** Structural landscapes of the six classes of RBD NAbs (upper panel). Antigenic
626 patches (with targeting frequency >30%) recognized by six classes of NAbs are
627 outlined in the assigned color scheme (same to Fig. 3C), among which residues with
628 “hot targeting frequency” (generally over 65%, but over 85% in class I) are shown
629 in bright colors corresponding to the patches they belong to. Residues involved in
630 two (such as Y489, L452) or three (such as F486) neighboring antigenic patches are
631 presented in a mixed color. Representative “hot” antigenic residues are labeled.
632 Middle: hot map for antigenic residues on the RBD. Per residue frequency
633 recognized by the 171 NAbs were calculated and shown. The top 9 of the hottest
634 antigenic residues and key residues with substitutions in several VOCs are marked
635 and labeled. Bottom: hot map for circulating variants with mutations on the RBD.
636 Mutation frequency for each residue was calculated based on the datasets from
637 GISAID.

638 **(E)** Immunogenic characteristics of six classes of RBD-targeting NAbs. Hot maps
639 show relative fold changes in K_D values (up) and IC_{50} values (down) against several
640 VOCs for the six classes of NAbs, including previously reported (97-108) and newly
641 isolated antibodies described in this manuscript. Color gradients for upper and
642 bottom panels indicate relative fold changes and are shown at right side. “-”: no
643 related datasets in the original studies and related references are listed. Ref “A”
644 indicates that the datasets were produced in this manuscript. Other letters in Ref
645 correspond to different reference numbers shown as below. B – 91 and this
646 manuscript, C – 99 and this manuscript, D – 97, E – 30, 81, 103 and 104, F – 99, G –
647 98, H – 100 and 108, J – 101, K – 94 and 102, L – 105 and 106, M – 94, N – 105, O
648 – 107, P – 82, Q – 66, respectively.



649

650 **Fig. 4 Antibody evolution and affinity maturation**

651 (A) Uniform manifold approximation and projection (UMAP) plot displaying the
 652 antibodies defined as the early time point group (left) and late time point group
 653 (right). The antibodies are colored based on their cluster assignments by the
 654 hierarchical clustering algorithm. Antibodies from I to III and IV to VI are
 655 highlighted in cyan and gray blue background, respectively. Pie charts represent the
 656 frequency distribution of antibodies belonging to I to III and IV to VI. Antibodies
 657 isolated from 3-dose vaccinees are outlined by black lines.

658 (B) Dissociation constants (K_D) of the antibodies from I to VI. Individual class
 659 antibodies are represented in colors corresponding to the classes they belong to. The
 660 color scheme is same as Fig. 4A. BLI traces are shown in fig. S9.

661 (C) The measured K_D -SHM plots (left) and K_D -SHM log-log plots (right) of
 662 antibodies from I and II are shown. *IGHV3-53* and *IGHV3-66* antibodies belonging
 663 to class I and II are colored in yellow and green, respectively. The straight curves
 664 and lines are the least squares fits of the data to the power law with the values of the
 665 slope for *IGHV3-53* and *IGHV3-66* antibodies. The black curves and lines indicate
 666 the fitting of antibodies from I or II; the yellow and green ones suggest the fitting of
 667 *IGHV3-53* and *IGHV3-66* antibodies, respectively. The cyan lines are the 90%
 668 predicted interval.

669

670

671 **References and Notes:**

- 672 1. N. G. Davies, S. Abbott *et al.*, Estimated transmissibility and impact of SARS-CoV-2 lineage
673 B.1.1.7 in England. *Science* **372**, (2021); published online EpubApr 9
674 (10.1126/science.abg3055).
- 675 2. Z. Wang, F. Schmidt *et al.*, mRNA vaccine-elicited antibodies to SARS-CoV-2 and
676 circulating variants. *nature*, 616–622 (2021)10.1038/s41586-021-03324-6).
- 677 3. A. Muik, A. K. Wallisch *et al.*, Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus
678 by BNT162b2 vaccine-elicited human sera. *Science* **371**, 1152-1153 (2021); published
679 online EpubMar 12 (10.1126/science.abg6105).
- 680 4. W. F. Garcia-Beltran, E. C. Lam *et al.*, Multiple SARS-CoV-2 variants escape neutralization
681 by vaccine-induced humoral immunity. *Cell* **184**, 2372-2383 e2379 (2021); published
682 online EpubApr 29 (10.1016/j.cell.2021.03.013).
- 683 5. E. Hacisuleyman, C. Hale *et al.*, Vaccine Breakthrough Infections with SARS-CoV-2
684 Variants. *N Engl J Med* **384**, 2212-2218 (2021); published online EpubJun 10
685 (10.1056/NEJMoa2105000).
- 686 6. E. C. Sabino, L. F. Buss *et al.*, Resurgence of COVID-19 in Manaus, Brazil, despite high
687 seroprevalence. *Lancet* **397**, 452-455 (2021); published online EpubFeb 6
688 (10.1016/S0140-6736(21)00183-5).
- 689 7. W. N. Chia, F. Zhu *et al.*, Dynamics of SARS-CoV-2 neutralising antibody responses and
690 duration of immunity: a longitudinal study. *The Lancet. Microbe* **2**, e240-e249 (2021);
691 published online EpubJun (10.1016/S2666-5247(21)00025-2).
- 692 8. A. T. Widge, N. G. Roupheal *et al.*, Durability of Responses after SARS-CoV-2 mRNA-1273
693 Vaccination. *N Engl J Med* **384**, 80-82 (2021); published online EpubJan 7
694 (10.1056/NEJMc2032195).
- 695 9. Y. Zhang, G. Zeng *et al.*, Safety, tolerability, and immunogenicity of an inactivated SARS-
696 CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-
697 controlled, phase 1/2 clinical trial. *Lancet Infect Dis* **21**, 181-192 (2021); published online
698 EpubFeb (10.1016/S1473-3099(20)30843-4).
- 699 10. Q. Gao, L. Bao *et al.*, Development of an inactivated vaccine candidate for SARS-CoV-2.
700 *Science* **369**, 77-81 (2020); published online EpubJul 3 (10.1126/science.abc1932).
- 701 11. D. S. Khoury, A. K. Wheatley *et al.*, Measuring immunity to SARS-CoV-2 infection:
702 comparing assays and animal models. *Nature reviews. Immunology* **20**, 727-738 (2020);
703 published online EpubDec (10.1038/s41577-020-00471-1).
- 704 12. L. Riepler, A. Rossler *et al.*, Comparison of Four SARS-CoV-2 Neutralization Assays.
705 *Vaccines* **9**, (2020); published online EpubDec 28 (10.3390/vaccines9010013).
- 706 13. Q. W. Hongxing Pan, G. Zeng, Immunogenicity and safety of a third dose, and immune
707 persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from
708 a double-blind, randomized, placebo-controlled phase 2 clinical trial. *medRxiv*,
709 (2021)<https://doi.org/10.1101/2021.07.23.21261026>).
- 710 14. Z. Wang, F. Muecksch *et al.*, Naturally enhanced neutralizing breadth against SARS-CoV-
711 2 one year after infection. *Nature* **595**, 426-431 (2021); published online EpubJul
712 (10.1038/s41586-021-03696-9).
- 713 15. F. Muecksch, Y. Weisblum *et al.*, Development of potency, breadth and resilience to viral
714 escape mutations in SARS-CoV-2 neutralizing antibodies. *bioRxiv*, (2021); published
715 online EpubMar 8 (10.1101/2021.03.07.434227).
- 716 16. C. Gaebler, Z. Wang *et al.*, Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**,
717 639-644 (2021); published online EpubMar (10.1038/s41586-021-03207-w).
- 718 17. Y. Zhou, Z. Liu *et al.*, Enhancement versus neutralization by SARS-CoV-2 antibodies from
719 a convalescent donor associates with distinct epitopes on the RBD. *Cell Rep* **34**, 108699
720 (2021); published online EpubFeb 2 (10.1016/j.celrep.2021.108699).
- 721 18. D. F. Robbiani, C. Gaebler *et al.*, Convergent antibody responses to SARS-CoV-2 in
722 convalescent individuals. *Nature* **584**, 437-442 (2020); published online EpubAug

- 723 (10.1038/s41586-020-2456-9).
- 724 19. A. C. Walls, Y. J. Park *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
725 Glycoprotein. *Cell* **181**, 281-292 e286 (2020); published online EpubApr 16
726 (10.1016/j.cell.2020.02.058).
- 727 20. D. Wrapp, N. Wang *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion
728 conformation. *Science* **367**, 1260-1263 (2020); published online EpubMar 13
729 (10.1126/science.abb2507).
- 730 21. R. Yan, R. Wang *et al.*, Structural basis for bivalent binding and inhibition of SARS-CoV-2
731 infection by human potent neutralizing antibodies. *Cell Res* **31**, 517-525 (2021); published
732 online EpubMay (10.1038/s41422-021-00487-9).
- 733 22. W. Dejnirattisai, D. Zhou *et al.*, The antigenic anatomy of SARS-CoV-2 receptor binding
734 domain. *Cell* **184**, 2183-2200 e2122 (2021); published online EpubApr 15
735 (10.1016/j.cell.2021.02.032).
- 736 23. M. Yuan, H. Liu *et al.*, Structural basis of a shared antibody response to SARS-CoV-2.
737 *Science* **369**, 1119-1123 (2020); published online EpubAug 28 (10.1126/science.abd2321).
- 738 24. F. Bertoglio, V. Fuhner *et al.*, A SARS-CoV-2 neutralizing antibody selected from COVID-
739 19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD
740 mutations. *Cell Rep* **36**, 109433 (2021); published online EpubJul 27
741 (10.1016/j.celrep.2021.109433).
- 742 25. S. A. Clark, L. E. Clark *et al.*, Molecular basis for a germline-biased neutralizing antibody
743 response to SARS-CoV-2. *bioRxiv*, (2020); published online EpubNov 13
744 (10.1101/2020.11.13.381533).
- 745 26. B. B. Banach, G. Cerutti *et al.*, Paired heavy and light chain signatures contribute to potent
746 SARS-CoV-2 neutralization in public antibody responses. *bioRxiv*, (2021); published
747 online EpubJan 3 (10.1101/2020.12.31.424987).
- 748 27. B. E. Jones, P. L. Brown-Augsburger *et al.*, The neutralizing antibody, LY-CoV555, protects
749 against SARS-CoV-2 infection in nonhuman primates. *Sci Transl Med* **13**, (2021);
750 published online EpubMay 12 (10.1126/scitranslmed.abf1906).
- 751 28. Y. Guo, L. Huang *et al.*, A SARS-CoV-2 neutralizing antibody with extensive Spike binding
752 coverage and modified for optimal therapeutic outcomes. *Nat Commun* **12**, 2623 (2021);
753 published online EpubMay 11 (10.1038/s41467-021-22926-2).
- 754 29. S. Du, Y. L. Cao *et al.*, Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in
755 Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. *Cell* **183**,
756 1013-+ (2020); published online EpubNov 12 (10.1016/j.cell.2020.09.035).
- 757 30. W. Dejnirattisai, D. M. Zhou *et al.*, Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell*
758 **184**, 2939-+ (2021); published online EpubMay 27 (10.1016/j.cell.2021.03.055).
- 759 31. C. O. Barnes, C. A. Jette *et al.*, SARS-CoV-2 neutralizing antibody structures inform
760 therapeutic strategies. *Nature* **588**, 682-+ (2020); published online EpubDec 24
761 (10.1038/s41586-020-2852-1).
- 762 32. N. C. Wu, M. Yuan *et al.*, An Alternative Binding Mode of IGHV3-53 Antibodies to the
763 SARS-CoV-2 Receptor Binding Domain. *Cell Reports* **33**, (2020); published online
764 EpubOct 20 (10.1016/J.Celrep.2020.108274).
- 765 33. H. J. Liu, N. C. Wu *et al.*, Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally
766 Conserved Site Is Mediated by Avidity. *Immunity* **53**, 1272-+ (2020); published online
767 EpubDec 15 (10.1016/j.immuni.2020.10.023).
- 768 34. N. K. Hurlburt, E. Seydoux *et al.*, Structural basis for potent neutralization of SARS-CoV-2
769 and role of antibody affinity maturation. *Nature Communications* **11**, (2020); published
770 online EpubOct 27 (10.1038/s41467-020-19231-9).
- 771 35. Y. Wu, F. R. Wang *et al.*, A noncompeting pair of human neutralizing antibodies block
772 COVID-19 virus binding to its receptor ACE2. *Science* **368**, 1274-+ (2020); published
773 online EpubJun 12 (10.1126/science.abc2241).

- 774 36. R. Shi, C. Shan *et al.*, A human neutralizing antibody targets the receptor-binding site of
775 SARS-CoV-2. *Nature* **584**, 120-+ (2020); published online EpubAug 6 (10.1038/s41586-
776 020-2381-y).
- 777 37. J. W. Ge, R. K. Wang *et al.*, Antibody neutralization of SARS-CoV-2 through ACE2 receptor
778 mimicry. *Nature Communications* **12**, (2021); published online EpubJan 11
779 (10.1038/s41467-020-20501-9).
- 780 38. C. O. Barnes, A. P. West *et al.*, Structures of Human Antibodies Bound to SARS-CoV-2
781 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-+
782 (2020); published online EpubAug 20 (10.1016/j.cell.2020.06.025).
- 783 39. H. P. Yao, Y. Sun *et al.*, Rational development of a human antibody cocktail that deploys
784 multiple functions to confer Pan-SARS-CoVs protection. *Cell Research* **31**, 25-36 (2021);
785 published online EpubJan (10.1038/s41422-020-00444-y).
- 786 40. N. Wang, Y. Sun *et al.*, Structure-based development of human antibody cocktails against
787 SARS-CoV-2. *Cell Research* **31**, 101-103 (2021); published online EpubJan
788 (10.1038/s41422-020-00446-w).
- 789 41. S. Miersch, Z. Li, Tetraivalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced
790 Potency and Resistance to Escape Mutations. *BioRxiv*,
791 (2021)<https://doi.org/10.1101/2020.10.31.362848>).
- 792 42. C. J. Bracken, S. A. Lim *et al.*, Bi-paratopic and multivalent VH domains block ACE2 binding
793 and neutralize SARS-CoV-2. *Nature chemical biology* **17**, 113-121 (2021); published
794 online EpubJan (10.1038/s41589-020-00679-1).
- 795 43. C. Zhang, Y. F. Wang *et al.*, Development and structural basis of a two-MAb cocktail for
796 treating SARS-CoV-2 infections. *Nature Communications* **12**, (2021); published online
797 EpubJan 11 (10.1038/s41467-020-20465-w).
- 798 44. L. Piccoli, Y. J. Park *et al.*, Mapping Neutralizing and Immunodominant Sites on the SARS-
799 CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
800 *Cell* **183**, 1024-+ (2020); published online EpubNov 12 (10.1016/j.cell.2020.09.037).
- 801 45. J. Hansen, A. Baum *et al.*, Studies in humanized mice and convalescent humans yield a
802 SARS-CoV-2 antibody cocktail. *Science* **369**, 1010-1014 (2020); published online
803 EpubAug 21 (10.1126/science.abd0827).
- 804 46. J. Kreye, S. M. Reincke *et al.*, A Therapeutic Non-self-reactive SARS-CoV-2 Antibody
805 Protects from Lung Pathology in a COVID-19 Hamster Model. *Cell* **183**, 1058-+ (2020);
806 published online EpubNov 12 (10.1016/j.cell.2020.09.049).
- 807 47. R. Rouet, O. Mazigi *et al.*, Potent SARS-CoV-2 binding and neutralization through
808 maturation of iconic SARS-CoV-1 antibodies. *Mabs-Austin* **13**, (2021); published online
809 EpubJan 1 (10.1080/19420862.2021.1922134).
- 810 48. M. A. Tortorici, M. Beltramello *et al.*, Ultrapotent human antibodies protect against SARS-
811 CoV-2 challenge via multiple mechanisms. *Science* **370**, 950-+ (2020); published online
812 EpubNov 20 (10.1126/science.abe3354).
- 813 49. E. Rujas, I. Kucharska *et al.*, Multivalency transforms SARS-CoV-2 antibodies into
814 ultrapotent neutralizers. *Nature Communications* **12**, (2021); published online EpubJun
815 16 (10.1038/S41467-021-23825-2).
- 816 50. J. Ahmad, J. Jiang *et al.*, Synthetic nanobody-SARS-CoV-2 receptor-binding domain
817 structures identify distinct epitopes. *bioRxiv*, (2021); published online EpubJan 27
818 (10.1101/2021.01.27.428466).
- 819 51. M. Schoof, B. Faust *et al.*, An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by
820 stabilizing inactive Spike. *Science* **370**, 1473-1479 (2020); published online EpubDec 18
821 (10.1126/science.abe3255).
- 822 52. M. Rapp, Y. C. Guo *et al.*, Modular basis for potent SARS-CoV-2 neutralization by a
823 prevalent VH1-2-derived antibody class. *Cell Reports* **35**, (2021); published online
824 EpubApr 6 (10.1016/J.Celrep.2021.108950).

- 825 53. C. Kim, D. K. Ryu *et al.*, A therapeutic neutralizing antibody targeting receptor binding
826 domain of SARS-CoV-2 spike protein. *Nature Communications* **12**, (2021); published
827 online EpubJan 12 (10.1038/s41467-020-20602-5).
- 828 54. D. Li, R. J. Edwards *et al.*, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing
829 and neutralizing antibodies. *Cell*, (2021); published online EpubJun 18
830 (10.1016/j.cell.2021.06.021).
- 831 55. L. Hanke, L. V. Perez *et al.*, An alpaca nanobody neutralizes SARS-CoV-2 by blocking
832 receptor interaction. *Nature Communications* **11**, (2020); published online EpubSep 4
833 (10.1038/s41467-020-18174-5).
- 834 56. J. D. Huo, A. Le Bas *et al.*, Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block
835 interaction with ACE2 (vol 27, pg 846, 2020). *Nature Structural & Molecular Biology* **28**,
836 326-326 (2021); published online EpubMar (10.1038/s41594-021-00566-w).
- 837 57. B. Ju, Q. Zhang *et al.*, Human neutralizing antibodies elicited by SARS-CoV-2 infection.
838 *Nature* **584**, 115-+ (2020); published online EpubAug 6 (10.1038/s41586-020-2380-z).
- 839 58. Y. L. Cao, B. Su *et al.*, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by
840 High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell* **182**, 73-
841 + (2020); published online EpubJul 9 (10.1016/j.cell.2020.05.025).
- 842 59. L. H. Liu, P. F. Wang *et al.*, Potent neutralizing antibodies against multiple epitopes on
843 SARS-CoV-2 spike. *Nature* **584**, 450-+ (2020); published online EpubAug 20
844 (10.1038/s41586-020-2571-7).
- 845 60. P. A. Koenig, H. Das *et al.*, Structure-guided multivalent nanobodies block SARS-CoV-2
846 infection and suppress mutational escape. *Science* **371**, 691-+ (2021); published online
847 EpubFeb 12 (10.1126/science.abe6230).
- 848 61. Y. F. Xiang, S. Nambulli *et al.*, Versatile and multivalent nanobodies efficiently neutralize
849 SARS-CoV-2. *Science* **370**, 1479-1484 (2020); published online EpubDec 18
850 (10.1126/science.abe4747).
- 851 62. L. Zhu, Y. Q. Deng *et al.*, Double lock of a potent human therapeutic monoclonal antibody
852 against SARS-CoV-2. *National Science Review* **8**, (2021); published online EpubMar
853 (10.1093/nsr/nwaa297).
- 854 63. G. Cerutti, M. Rapp *et al.*, Structural basis for accommodation of emerging B.1.351 and
855 B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. *Structure* **29**, 655-+
856 (2021); published online EpubJul 1 (10.1016/j.str.2021.05.014).
- 857 64. T. F. Custodio, H. Das *et al.*, Selection, biophysical and structural analysis of synthetic
858 nanobodies that effectively neutralize SARS-CoV-2. *Nature Communications* **11**, (2020);
859 published online EpubNov 4 (10.1038/s41467-020-19204-Y).
- 860 65. J. F. Scheid, C. O. Barnes *et al.*, B cell genomics behind cross-neutralization of SARS-CoV-
861 2 variants and SARS-CoV. *Cell* **184**, 3205-+ (2021); published online EpubJun 10
862 (10.1016/j.cell.2021.04.032).
- 863 66. H. J. Liu, M. Yuan *et al.*, A combination of cross-neutralizing antibodies synergizes to
864 prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. *Cell Host & Microbe* **29**, 806-
865 + (2021); published online EpubMay 12 (10.1016/j.chom.2021.04.005).
- 866 67. D. Pinto, Y. J. Park *et al.*, Cross-neutralization of SARS-CoV-2 by a human monoclonal
867 SARS-CoV antibody. *Nature* **583**, 290-295 (2020); published online EpubJul
868 (10.1038/s41586-020-2349-y).
- 869 68. T. N. Starr, N. Czudnochowski *et al.*, Antibodies to the SARS-CoV-2 receptor-binding
870 domain that maximize breadth and resistance to viral escape. *bioRxiv*, (2021).
- 871 69. D. M. Zhou, H. M. E. Duyvesteyn *et al.*, Structural basis for the neutralization of SARS-
872 CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular Biology*
873 **27**, 950-+ (2020); published online EpubOct (10.1038/s41594-020-0480-y).
- 874 70. M. Yuan, N. C. Wu *et al.*, A highly conserved cryptic epitope in the receptor binding
875 domains of SARS-CoV-2 and SARS-CoV. *Science* **368**, 630-+ (2020); published online

876 EpubMay 8 (10.1126/science.abb7269).

877 71. Z. Lv, Y. Q. Deng *et al.*, Structural basis for neutralization of SARS-CoV-2 and SARS-CoV
878 by a potent therapeutic antibody. *Science* **369**, 1505-+ (2020); published online EpubSep
879 18 (10.1126/science.abc5881).

880 72. Y. L. Cao, A. Yisimayi *et al.*, Humoral immune response to circulating SARS-CoV-2 variants
881 elicited by inactivated and RBD-subunit vaccines. *Cell Research* **31**, 732-741 (2021);
882 published online EpubJul (10.1038/s41422-021-00514-9).

883 73. Y. Sun, L. Wang *et al.*, Structure-based development of three- and four-antibody cocktails
884 against SARS-CoV-2 via multiple mechanisms. *Cell Research* **31**, 597-600 (2021);
885 published online EpubMay (10.1038/s41422-021-00497-7).

886 74. X. Zhu, D. Mannar *et al.*, Cryo-electron microscopy structures of the N501Y SARS-CoV-2
887 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. *PLoS Biol* **19**,
888 e3001237 (2021); published online EpubApr (10.1371/journal.pbio.3001237).

889 75. D. Asarnow, B. Wang *et al.*, Structural insight into SARS-CoV-2 neutralizing antibodies
890 and modulation of syncytia. *Cell* **184**, 3192-+ (2021); published online EpubJun 10
891 (10.1016/j.cell.2021.04.033).

892 76. X. J. Zhou, F. G. Ma *et al.*, Diverse immunoglobulin gene usage and convergent epitope
893 targeting in neutralizing antibody responses to SARS-CoV-2. *Cell Reports* **35**, (2021);
894 published online EpubMay 11 (10.1016/j.celrep.2021.109109).

895 77. M. F. Jennewein, A. J. MacCamy *et al.*, Isolation and characterization of cross-neutralizing
896 coronavirus antibodies from COVID-19+ subjects. *Cell Rep* **36**, 109353 (2021); published
897 online EpubJul 13 (10.1016/j.celrep.2021.109353).

898 78. T. N. Starr, N. Czudnochowski *et al.*, SARS-CoV-2 RBD antibodies that maximize breadth
899 and resistance to escape. *Nature*, 1-9 (2021).

900 79. J. Fedry, D. L. Hurdiss *et al.*, Structural insights into the cross-neutralization of SARS-CoV
901 and SARS-CoV-2 by the human monoclonal antibody 47D11. *Science Advances* **7**,
902 (2021); published online EpubJun (10.1126/sciadv.abf5632).

903 80. K. Westendorf, S. Zentelis *et al.*, LY-CoV1404 potently neutralizes SARS-CoV-2 variants.
904 *bioRxiv*, (2021); published online EpubMay 4 (10.1101/2021.04.30.442182).

905 81. C. Liu, H. M. Ginn *et al.*, Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and
906 convalescent serum. *Cell*, (2021); published online EpubJun 17
907 (10.1016/j.cell.2021.06.020).

908 82. L. Wang, T. Zhou *et al.*, Ultrapotent antibodies against diverse and highly transmissible
909 SARS-CoV-2 variants. *Science*, (2021); published online EpubJul 1
910 (10.1126/science.abh1766).

911 83. L. Zhang, L. Cao *et al.*, A proof of concept for neutralizing antibody-guided vaccine design
912 against SARS-CoV-2. *National Science Review*, (2020)10.1093/nsr/nwab053).

913 84. J. Huo, Y. Zhao *et al.*, Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
914 *Cell Host Microbe* **28**, 445-454 e446 (2020); published online EpubSep 9
915 (10.1016/j.chom.2020.06.010).

916 85. M. McCallum, A. De Marco *et al.*, N-terminal domain antigenic mapping reveals a site of
917 vulnerability for SARS-CoV-2. *Cell* **184**, 2332-2347 e2316 (2021); published online
918 EpubApr 29 (10.1016/j.cell.2021.03.028).

919 86. G. Cerutti, Y. Guo *et al.*, Potent SARS-CoV-2 neutralizing antibodies directed against spike
920 N-terminal domain target a single supersite. *Cell Host Microbe* **29**, 819-833 e817 (2021);
921 published online EpubMay 12 (10.1016/j.chom.2021.03.005).

922 87. X. Y. Chi, R. H. Yan *et al.*, A neutralizing human antibody binds to the N-terminal domain
923 of the Spike protein of SARS-CoV-2. *Science* **369**, 650-+ (2020); published online
924 EpubAug 7 (10.1126/science.abc6952).

925 88. W. N. Voss, Y. X. J. Hou *et al.*, Prevalent, protective, and convergent IgG recognition of
926 SARS-CoV-2 non-RBD spike epitopes. *Science* **372**, 1108-+ (2021); published online

- 927 EpubJun 4 (10.1126/science.abg5268).
- 928 89. A. Rosa, V. E. Pye *et al.*, SARS-CoV-2 can recruit a heme metabolite to evade antibody
929 immunity. *Science Advances* **7**, (2021); published online EpubMay
930 (10.1126/sciadv.abg7607).
- 931 90. Y. F. Liu, W. T. Soh *et al.*, An infectivity-enhancing site on the SARS-CoV-2 spike protein
932 targeted by antibodies. *Cell* **184**, 3452-+ (2021); published online EpubJun 24
933 (10.1016/j.cell.2021.05.032).
- 934 91. P. J. M. Brouwer, T. G. Caniels *et al.*, Potent neutralizing antibodies from COVID-19
935 patients define multiple targets of vulnerability. *Science* **369**, 643-+ (2020); published
936 online EpubAug 7 (10.1126/science.abc5902).
- 937 92. T. Noy-Porat, A. Mechaly *et al.*, Therapeutic antibodies, targeting the SARS-CoV-2 spike
938 N-terminal domain, protect lethally infected K18-hACE2 mice. *Isience* **24**, (2021);
939 published online EpubMay 21 (10.1016/j.isci.2021.102479).
- 940 93. J. Goike, C. L. Hsieh *et al.*, Synthetic repertoires derived from convalescent COVID-19
941 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary
942 binding modality. *bioRxiv*, (2021); published online EpubApr 9
943 (10.1101/2021.04.07.438849).
- 944 94. P. Wang, M. S. Nair *et al.*, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
945 *Nature* **593**, 130-135 (2021); published online EpubMay (10.1038/s41586-021-03398-2).
- 946 95. J. Lopez Bernal, N. Andrews *et al.*, Effectiveness of Covid-19 Vaccines against the B.1.617.2
947 (Delta) Variant. *N Engl J Med*, (2021); published online EpubJul 21
948 (10.1056/NEJMoa2108891).
- 949 96. A. Sheikh, J. McMenamin *et al.*, SARS-CoV-2 Delta VOC in Scotland: demographics, risk
950 of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461-2462 (2021); published
951 online EpubJun 26 (10.1016/S0140-6736(21)01358-1).
- 952 97. R. Wang, Q. Zhang *et al.*, Analysis of SARS-CoV-2 variant mutations reveals neutralization
953 escape mechanisms and the ability to use ACE2 receptors from additional species.
954 *Immunity* **54**, 1611-1621 e1615 (2021); published online EpubJul 13
955 (10.1016/j.immuni.2021.06.003).
- 956 98. P. L. Shuo Du, Zhiying Zhang, Structures of SARS-CoV-2 B.1.351 neutralizing antibodies
957 provide insights into cocktail design against concerning variants. *bioRxiv*,
958 (2021)<https://doi.org/10.1101/2021.07.30.454402>.
- 959 99. M. Yuan, D. Huang *et al.*, Structural and functional ramifications of antigenic drift in recent
960 SARS-CoV-2 variants. *Science*, (2021); published online EpubMay 20
961 (10.1126/science.abh1139).
- 962 100. R. T. E. Chen, X. W. Zhang *et al.*, Resistance of SARS-CoV-2 variants to neutralization by
963 monoclonal and serum-derived polyclonal antibodies. *Nature Medicine* **27**, (2021);
964 published online EpubApr (10.1038/s41591-021-01294-w).
- 965 101. D. K. Ryu, R. Song *et al.*, Therapeutic effect of CT-P59 against SARS-CoV-2 South African
966 variant. *Biochem Biophys Res Commun* **566**, 135-140 (2021); published online EpubAug
967 20 (10.1016/j.bbrc.2021.06.016).
- 968 102. P. Wang, R. G. Casner *et al.*, Increased resistance of SARS-CoV-2 variant P.1 to antibody
969 neutralization. *Cell Host Microbe* **29**, 747-751 e744 (2021); published online EpubMay 12
970 (10.1016/j.chom.2021.04.007).
- 971 103. D. Zhou, W. Dejnirattisai *et al.*, Evidence of escape of SARS-CoV-2 variant B.1.351 from
972 natural and vaccine-induced sera. *Cell* **184**, 2348-2361 e2346 (2021); published online
973 EpubApr 29 (10.1016/j.cell.2021.02.037).
- 974 104. P. Supasa, D. Zhou *et al.*, Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by
975 convalescent and vaccine sera. *Cell* **184**, 2201-2211 e2207 (2021); published online
976 EpubApr 15 (10.1016/j.cell.2021.02.033).
- 977 105. X. Y. Shen, H. L. Tang *et al.*, SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing

978 antibodies elicited by ancestral spike vaccines. *Cell Host & Microbe* **29**, 529-+ (2021);
979 published online EpubApr 14 (10.1016/j.chom.2021.03.002).
980 106. D. R. Martinez, A. Schaefer *et al.*, A broadly neutralizing antibody protects against SARS-
981 CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice. *bioRxiv*, (2021);
982 published online EpubApr 28 (10.1101/2021.04.27.441655).
983 107. D. A. Collier, A. De Marco *et al.*, Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-
984 elicited antibodies. *Nature* **593**, 136-141 (2021); published online EpubMay
985 (10.1038/s41586-021-03412-7).
986 108. R. E. Chen, E. S. Winkler *et al.*, In vivo monoclonal antibody efficacy against SARS-CoV-2
987 variant strains. *Nature*, (2021); published online EpubJun 21 (10.1038/s41586-021-
988 03720-y).

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013